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The protein a-synuclein accumulates in the brain of
patients with sporadic Parkinson’s disease (PD),
and increased gene dosage causes a severe, domi-
nantly inherited form of PD, but we know little about
the effects of synuclein that precede degeneration.
a-Synuclein localizes to the nerve terminal, but the
knockout has little if any effect on synaptic transmis-
sion. In contrast, we now find that the modest over-
expression of a-synuclein, in the range predicted
for gene multiplication and in the absence of overt
toxicity, markedly inhibits neurotransmitter release.
The mechanism, elucidated by direct imaging of the
synaptic vesicle cycle, involves a specific reduction
in size of the synaptic vesicle recycling pool. Ultra-
structural analysis demonstrates reduced synaptic
vesicle density at the active zone, and imaging
further reveals a defect in the reclustering of synaptic
vesicles after endocytosis. Increased levels of a-syn-
uclein thus produce a specific, physiological defect
in synaptic vesicle recycling that precedes detect-
able neuropathology.
INTRODUCTION
Many neurodegenerative diseases are associated with the accu-
mulation of a characteristic protein, and human genetics has
linked mutations in several of them to familial forms of degenera-
tion, indicating a causative role. However, the mechanism by
which these proteins cause degeneration remains unknown. In
particular, we do not know whether they produce disease
through the gain of an abnormal function, such as multimerization
(Haass and Selkoe, 2007), or an increase in their normal function.
Indeed, we know remarkably little about the physiological role of
most proteins that accumulate in neurodegenerative disease.
The protein a-synuclein (asyn) accumulates in the Lewy
bodies and dystrophic neurites characteristic of idiopathic66 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.Parkinson’s disease (PD) and Lewy body dementia (LBD) (Spill-
antini et al., 1998; Dickson, 2001). Point mutations in asyn are
also linked to an autosomal-dominant form of PD (Polymeropou-
los et al., 1997; Kru¨ger et al., 1998; Zarranz et al., 2004). Taken
together, these observations suggest a causative role for asyn
in sporadic as well as inherited PD and LBD. In addition, duplica-
tion and triplication of the asyn gene suffice to cause a severe,
highly penetrant form of PD (Singleton et al., 2003; Chartier-
Harlin et al., 2004), and polymorphisms in regulatory elements
of the asyn gene predispose to PD (Maraganore et al., 2006),
supporting a role for overexpression of the wild-type protein in
pathogenesis.
aSyn is a small (140 amino acid), peripheral membrane protein
that localizes specifically to the axon terminal in neurons, sug-
gesting a role in neurotransmitter release (Maroteaux et al.,
1988; Iwai et al., 1995). Indeed, the protein has been implicated
in the synaptic plasticity associated with song acquisition by
birds (George et al., 1995). The N terminus ofasyn contains seven
eleven-residue repeats that form an amphipathic helix on
membrane binding (Davidson et al., 1998; Bussell and Eliezer,
2003), and this membrane binding contributes to its presynaptic
localization (Fortin et al., 2004). However, the role of asyn in
synaptic transmission has remained unclear. Mice lacking asyn
have been reported to show either no or very small (and
opposing) effects on transmitter release (Abeliovich et al., 2000;
Cabin et al., 2002; Chandra et al., 2004; Yavich et al., 2004).
In contrast to the minimal phenotype of synuclein knockout
mice, recent work in model organisms has shown that the
overexpression of asyn produces considerable toxicity. Overex-
pression in yeast and Drosophila causes a defect in vesicular
transport between the endoplasmic reticulum and Golgi com-
plex that can be rescued by overexpression of rab proteins
(Cooper et al., 2006; Gitler et al., 2008). However, these organ-
isms lack a synuclein homolog, and wild-type synuclein exerts
much less if any toxicity in mammalian systems (Zhou et al.,
2000; Petrucelli et al., 2002; Manning-Bog et al., 2003; Chandra
et al., 2005; Cooper et al., 2006). More recently, overexpression
of asyn has been shown to inhibit catecholamine release from
adrenal chromaffin cells and granule release from platelets
(Park et al., 2002; Larsen et al., 2006), but we know little about
the effects of overexpression on synaptic transmission.
Figure 1. Overexpression of a-Synuclein
Inhibits Synaptic Vesicle Exocytosis
(A) Time course of changes in the fluorescence of
VGLUT1-pHluorin during and after 10 Hz stimula-
tion for 60 s in neurons cotransfected with either
wild-type human asyn or empty vector. Alkaliniza-
tion with 50 mM NH4Cl reveals total VGLUT1-
pHluorin (arrow). n = 3 coverslips, 60 boutons for
each condition.
(B) Total fluorescence of VGLUT1-pHluorin
revealed by the addition of NH4Cl shows that
expression of the reporter on all synaptic vesicles
is not altered by the overexpression of asyn.
Values are normalized to the fluorescence
obtained in vector control.
(C) The rate of endocytosis (t) at the end of 10 Hz
stimulation was determined by the fit to a single
exponential and shows no effect of asyn overex-
pression.
(D) Peak DF/F0 normalized to vector control shows
a reduction in cells overexpressing wild-type asyn.
*p < 0.05 for asyn versus control, two-tailed,
unpaired t test.
For panels (B)–(D), n = 9 coverslips, 180 nerve
terminals from each condition and 3 independent
transfections.
(E) Frequency histogram of peakDF/F0 from a large
number of synapses in response to 10 Hz stimula-
tion for 60 s. n = 9 coverslips from 3 independent
transfections, 1809 boutons for vector, and 1428
boutons for asyn.
(F) Time course of VGLUT1-pHluorin fluorescence
change during and after 10 Hz stimulation for 60 s
in hippocampal neurons from either wild-type or
a-synuclein knockout mice. n = 3 coverslips,
60 boutons for each condition.
(G) Peak DF/F0 after a 10 Hz 60 s stimulus normalized to total synaptic vesicle pool size (revealed by addition of NH4Cl) shows no significant difference between
wild-type and either asyn KO or a/b double KO neurons. n = 6 coverslips, 120 nerve terminals from each condition with 2 independent transfections. Values repre-
sent mean ± SEM.
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Since the loss of asyn has been reported to have little effect on
synaptic transmission, but overexpression of the wild-type
human protein causes PD and membrane trafficking defects in
yeast, we examined the effects of overexpression on transmitter
release. To study presynaptic effects directly, we used optical
imaging with a fusion of vesicular glutamate transporter 1
(VGLUT1) to the modified GFP ecliptic pHluorin (VGLUT1-
pHluorin) (Voglmaier et al., 2006). Expressed in primary neuronal
culture as a fusion to VGLUT1 or other synaptic vesicle proteins,
the fluorescence of lumenally oriented pHluorin is quenched by
the low pH of resting synaptic vesicles, increases during exocy-
tosis on exposure to the more alkaline extracellular medium, and
decreases as a result of the acidification that accompanies
endocytosis (Miesenbo¨ck et al., 1998). VGLUT1-pHluorin thus
monitors synaptic vesicle exo- and endocytosis in real time.
We cotransfected this reporter with either wild-type human
asyn or empty vector into dissociated embryonic hippocampal
neurons. Fixed at 2–3 weeks in vitro and stained with a human
asyn-specific antibody, the cultures show complete colocaliza-
tion of human asyn with VGLUT1-pHluorin at synaptic boutons
(Figure S1A). To assess the extent of overexpression, we usedan antibody that recognizes both human and endogenous rat
proteins (Figure S1B). Quantitation of the immunofluorescence
shows expression of asyn at levels 2- to 3-fold over endogenous
(Figure S1C), very similar to the overexpression predicted for
humans with a triplication of the asyn gene locus (Miller et al.,
2004). Consistent with previous results in vitro and in vivo (Mat-
suoka et al., 2001; Giasson et al., 2002; Lee et al., 2002; Fortin
et al., 2005), we also observe no obvious toxicity related to the
overexpression of asyn, and no asyn-immunoreactive deposits
in the overexpressing cells (Figures S1A and S1B).
Overexpression of a-Synuclein Inhibits Synaptic Vesicle
Exocytosis
To determine whether the increased expression of asyn affects
synaptic vesicle cycling, we subjected the transfected neurons
to field stimulation and imaged VGLUT1-pHluorin. Relative to
control, neurons overexpressing wild-type asyn show less
increase in fluorescence due to stimulation (Figures 1A, S1D,
and S1E). Since asyn has been shown to disrupt membrane traf-
ficking early in the secretory pathway of yeast (Cooper et al.,
2006; Gitler et al., 2008), we used NH4Cl to alkalinize acidic intra-
cellular compartments and reveal the intracellular pool of
quenched VGLUT1-pHluorin at boutons. Figure 1B shows thatNeuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc. 67
Figure 2. a-Synuclein Overexpression in Trans-
genic Mice Inhibits Synaptic Transmission
(A) Brain sections from 3-week-old transgenic mice (tg)
and wild-type (wt) littermates were double stained for
human asyn using the 15G7 antibody and for synapsins
using an antibody that recognizes both synapsins I and II.
(B) Extracts (10 mg) from cortex or hippocampus of asyn
transgenic mice and wt littermates were immunoblotted
in triplicate using an antibody to actin and the syn-1 anti-
body to both mouse and human asyn.
(C) Quantitation of the western analysis shown in (B)
indicates 3-fold overexpression of a-synuclein in the
transgenic mice. Samples from each animal were loaded
in triplicate, and syn-1 immunoreactivity normalized to
actin detected in the same blot. n = 3 animals.
(D) Representative fEPSP traces from CA1 stratum
radiatum of 3- to 5-week-old transgenic mice and wild-
type littermates in response to increasing stimulation of
Schaffer collaterals (left). An input-output curve of fiber
volley amplitude versus fEPSP slope shows significantly
less postsynaptic response by asyn transgenic mice
than wild-type littermates (right). p < 0.005 for all points
by two-tailed t test; n = 44 slices for wt, 48 slices for trans-
genic mice from 11 mice for each.
(E) fEPSP response in CA1 stratum radiatum to paired-
pulse stimulation of Schaffer collaterals with a 40 ms inter-
stimulus interval. The left panel shows representative
fEPSPs recorded from slices of wild-type (top) and trans-
genic animals (bottom). p < 0.05 by unpaired, two-tailed t
test; n = 45 slices for wt and 47 for transgenic mice.
(F) Transgenic overexpression of asyn reduces the
frequency of spontaneous release (right) but not mEPSC
amplitude (left). Values represent mean ± SEM.
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groups, and hence cannot account for the difference in response
to stimulation. Plotting the frequency of all responses as a func-
tion ofDF/F0, overexpression of asyn shifts the entire peak to the
left (Figure 1E), indicating effects on exocytosis at all synapses,
rather than a discrete subpopulation.
We then used the VGLUT1-pHluorin reporter to image other
aspects of the synaptic vesicle cycle. aSyn overexpression
does not affect the time course of fluorescence decay after the
stimulus (Figure 1C), excluding an effect on compensatory endo-
cytosis. However, asyn also fails to alter the rate of fluorescence
increase due to exocytosis. Rather, quantitation of peak DF/F0
shows a specific effect of asyn on the extent rather than the
rate of synaptic vesicle exocytosis (Figure 1D). The effect of
human asyn overexpression also appears early in the stimulus,
before VGLUT1-pHluorin has accumulated on the cell surface
at levels high enough to detect its internalization (Voglmaier
et al., 2006), further excluding effects on endocytosis that might
occur specifically during the stimulus (Ferguson et al., 2007).68 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.Since most neurons express substantial
amounts of endogenous asyn, we also overex-
pressed the human protein in postnatal hippo-
campal cultures from asyn knockout (KO) mice
(Abeliovich et al., 2000). Human asyn has
roughly the same effect on evoked synaptic
vesicle exocytosis as in hippocampal culturesfrom rat (Figure S1F). To determine more directly whether endog-
enous asyn affects release, we also transfected VGLUT1-
pHluorin alone into postnatal hippocampal cultures from asyn
KO mice and wild-type littermates. The KO shows a trend toward
increased evoked transmitter release, but the difference does not
reach statistical significance (Figures 1F and 1G). In the same
experimental paradigm, the overexpression of asyn thus has
a greater effect on transmitter release than the loss of synuclein.
Inhibition of Synaptic Transmission in Transgenic Mice
Overexpressing a-Synuclein
To determine whether asyn influences synaptic transmission
in vivo, we used electrophysiology to record the postsynaptic
response in acute hippocampal slices from transgenic mice
overexpressing wild-type human asyn. Produced using se-
quences from the prion promoter that drive widespread asyn
expression in neurons (Figure 2A), the transgenic mice express
asyn 3-fold over endogenous by quantitative western analysis
with the antibody that recognizes both rodent and human asyn
Figure 3. a-Synuclein Inhibits Synaptic Vesicle
Exocytosis in Midbrain Dopamine Neurons
(A) Postnatal midbrain neurons cotransfected with
VGLUT1-pHluorin and either human asyn or empty vector
were grown for 14–21 DIV and immunostained for human
asyn using the human-specific asyn antibody 15G7, for
VGLUT1-pHluorin using a monoclonal antibody to GFP,
and for tyrosine hydroxylase (TH) using a polyclonal anti-
body. Arrowheads indicate TH+ boutons expressing
VGLUT1-pHluorin with or without human asyn. Scale
bar, 5 mm.
(B) Time course of response to 10 Hz stimulation for 60 s
by TH+ neurons expressing VGLUT1-pHluorin and either
wild-type human asyn or empty vector. (Inset) Peak DF/F0
values normalized to the response by cells transfected
with empty vector. p < 0.001, n = 7 coverslips, 116 nerve
terminals for vector, and 8 coverslips, 84 nerve terminals
for asyn from 2 independent transfections. Values indicate
mean ± SEM.
Neuron
a-Synuclein Inhibits Neurotransmitter Release(Figures 2B and 2C), very similar to the overexpression in culture.
We also observed no obvious pathology orasyn-immunoreactive
deposits by light microscopy, or asyn-immunoreactive aggre-
gates by western analysis (Figure S2). Using hippocampal slices
from transgenic animals and wild-type littermates, we recorded
field excitatory postsynaptic potentials (fEPSPs) from synapses
made by CA3 Schaffer collaterals onto dendrites in CA1 stratum
radiatum. The transgenic mice show significantly less baseline
transmission than wild-type at a range of stimulus intensities
(Figure 2D), and the extent of inhibition resembles that observed
for asyn overexpression in culture. To determine whether the
reduction reflects a presynaptic effect, we measured the
paired-pulse ratio (PPR). Schaffer collaterals characteristically
show facilitation due to residual Ca2+ in the terminal, and manip-
ulations that inhibit release generally increase PPR. Consistent
with a presynaptic mechanism, we observe a small but significant
increase in PPR (Figure 2E). Further, the overexpression of synu-
clein reduces the frequency of spontaneous release without
affecting quantal size (Figure 2F). The analysis of synaptic trans-
mission in brain slices thus strongly supports the physiological
significance of impaired synaptic vesicle exocytosis observed
in dissociated culture.
a-Synuclein Inhibits Synaptic Vesicle Exocytosis
in Midbrain Dopamine Neurons
Since the loss of dopamine neurons from the substantia nigra is
a defining feature of PD, we also cotransfected human asyn withNeuron 65VGLUT1-pHluorin into postnatal cultures from
the rat ventral midbrain, which have indeed
been shown to release glutamate as well as
dopamine and express the related isoform
VGLUT2 (Sulzer et al., 1998; Dal Bo et al.,
2004). These cultures typically contain more
than 90% dopamine neurons, but all the cover-
slips were fixed and immunostained for TH to
select catecholamine boutons for analysis
(Figure 3A). Similar to hippocampal neurons,
dopamine neurons that overexpress asynshow less synaptic vesicle exocytosis than control transfected
dopamine neurons (Figure 3B). The effect appears greater than
in hippocampal neurons, but this may reflect differences in the
properties of release by dopamine neurons rather than a different
effect of asyn. Indeed, the properties of synaptic vesicle recy-
cling by dopamine neurons remain poorly understood, and since
the overall effect of asyn overexpression appears similar in both
culture systems, we have further characterized the mechanism
in hippocampal neurons, which normally express asyn and
accumulate the protein in both advanced PD and Lewy body
dementia (Braak et al., 2003).
Overexpression of a-Synuclein Reduces the Readily
Releasable and Recycling Synaptic Vesicle Pools
aSyn may interfere with synaptic vesicle mobilization, priming,
docking, or fusion. To assess an effect on fusion, we examined
the release of vesicles docked and primed for exocytosis (the
readily releasable pool, or RRP). Stimulating at 30 Hz for 3 s,
which activates selectively the RRP (Pyle et al., 2000), asyn over-
expression inhibits release to the same extent as with more pro-
longed stimulation (Figure 4A). The response to hypertonic
sucrose has also been used to define the RRP (Rosenmund
and Stevens, 1996), but changes in refractive index complicate
the imaging. We therefore used the vacuolar H+-ATPase inhibitor
bafilomycin to prevent reacidification of the vesicles that had
undergone exocytosis and imaged the cells just before the addi-
tion of hypertonic sucrose and after, when the cells had been, 66–79, January 14, 2010 ª2010 Elsevier Inc. 69
Figure 4. a-Synuclein Reduces the Recycling Pool of Synaptic Vesicles
(A) Hippocampal neurons cotransfected with VGLUT1-pHluorin and either human asyn or empty vector were stimulated at 30 Hz for 3 s to activate specifically the
readily releasable pool of synaptic vesicles. n = 3 coverslips, 60 boutons per condition. (Inset) Peak DF/F0 values normalized to the response in the vector control
shows a substantial reduction in the cells overexpressing human asyn. n = 6 coverslips, 120 boutons per condition from 2 independent transfections. p < 0.0001
by two-tailed, unpaired t test.
(B) Neurons expressing VGLUT1-pHluorin were stimulated with Tyrode’s solution containing 500 mM sucrose in the presence of 1 mM bafilomycin to prevent
reacidification of the internalized vesicles and imaged in the absence of sucrose (to avoid distortion by changes in refractive index) both before and after stim-
ulation. The change in DF/F0 normalized to vector control shows a reduction in neurons overexpressing human asyn. n = 9 coverslips, 180 boutons per condition
from 3 independent transfections. p < 0.05 by two-tailed, unpaired t test.
(C) Hippocampal neurons transfected with either asyn-IRES2-GFP or IRES2-GFP were loaded with 15 mM FM4-64 by 10 Hz stimulation for 60 s, maintained in the
dye for 60 additional seconds to allow full endocytosis, and washed extensively before destaining at 10 Hz for 120 s. n = 3 coverslips, 71 boutons for asyn-trans-
fected, 73 nerve terminals for vector. asyn overexpression reduces the amount of releasable dye uptake (inset). p < 0.05, n = 6 coverslips, 153 boutons for asyn-
overexpressing cells, and 208 boutons for vector control from 2 independent transfections.
(D) Hippocampal neurons transfected with VGLUT1-pHluorin and either human asyn or empty vector were stimulated at 10 Hz for 150 s in the presence of 1 mM
bafilomycin to reveal the full recycling pool, followed by treatment with NH4Cl (arrow) to reveal the total synaptic vesicle pool. n = 60 boutons from 3 coverslips for
each condition.
(E) (Left panel) Cultures were transfected and stimulated as in (D) but with controls stimulated in the presence of 1 mM as well as 2 mM Ca2+. n = 60 boutons from
3 coverslips per condition. (Right panel) Peak DF/F0 before addition of NH4Cl (normalized to 2 mM Ca
2+ control) shows a reduction in the presence of overex-
pressed asyn but no significant reduction of control boutons stimulated in 1 mM Ca2+. p < 0.01 by one-way ANOVA with Tukey’s post hoc tests, p > 0.05 for vector
in 2 mM Ca2+ versus vector in 1 mM Ca2+, p < 0.01 for vector in 2 mM Ca2+ versus asyn in 2 mM Ca2+, and p < 0.05 for vector in 1 mM Ca2+ versus asyn in 2 mM
Ca2+. n = 120 boutons from 6 coverslips per condition and 2 independent transfections. Values represent mean ± SEM.
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decreases peak fluorescence (Figure 4B), supporting an effect
of asyn on the RRP. Since release by hypertonic sucrose does
not require calcium (Rosenmund and Stevens, 1996), the effect
of asyn on synaptic vesicle exocytosis cannot involve a change
in calcium entry or sensitivity.
The reduction in RRP by asyn suggests a defect in synaptic
vesicle exocytosis at or close to the fusion event, but could
also result from a decrease in the number of available vesicles,
with no change in the rate of fusion. To distinguish between these
possibilities, we examined uptake of the styryl dye FM4-64 by70 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.neurons coexpressing asyn and GFP (to identify the transfected
cells) or GFP alone. After loading by stimulation at 10 Hz for 60 s,
and incubation in dye for an additional 60 s to allow full endocy-
tosis, the neurons were unloaded by 10 Hz stimulation for 120 s.
The amount of dye released by the second stimulus provides
a measure of the vesicle pool available for release (recycling
pool). Boutons expressing asyn show an 50% decrease in
the amount of specific FM dye uptake (Figure 4C), supporting
the results with VGLUT1-pHluorin. However, the rate of dye
efflux shows no effect of asyn overexpression (t = 49.8 ± 9.5 s
for vector, t = 37.9 ± 5.9 s for asyn, p = 0.32). aSyn thus reduces
Neuron
a-Synuclein Inhibits Neurotransmitter Releasethe size of the synaptic vesicle recycling pool without affecting
the kinetics of fusion. Since RRP size generally scales with the
size of the recycling pool (Mozhayeva et al., 2002), the effect of
asyn on RRP presumably reflects the reduction in recycling
pool size.
The size of the synaptic vesicle recycling pool can also be
measured by stimulating neurons that express VGLUT1-
pHluorin in the presence of the H+ pump inhibitor bafilomycin.
Since bafilomycin blocks synaptic vesicle reacidification after
endocytosis, prolonged stimulation results in the accumulation
of unquenched reporter in all the synaptic vesicles that have
undergone exocytosis, to reveal the entire recycling pool.
Figure 4D shows that asyn reduces the size of the recycling
pool with no change in the total vesicle pool size revealed by
NH4Cl, consistent with the results obtained using FM4-64.
However, slowed release might cause an apparent reduction in
recycling pool size if stimulation does not persist long enough
to release all the vesicles in the recycling pool. To address this
possibility, we identified a concentration of external calcium
that reduces the initial rate of fluorescence increase to that
observed with asyn overexpression. In 1 mM Ca2+, control cells
(expressing VGLUT1-pHluorin but not human asyn) show an
initial rate of fluorescence increase very similar to that of cells
expressing human asyn, but with prolonged stimulation in
bafilomycin, show a recycling pool size approaching that of
control cells in 2 mM Ca2+ (Figure 4E). In contrast, the recycling
pool of cells expressing asyn (in 2 mM Ca2+) never approaches
that of controls. Thus, asyn overexpression decreases specifi-
cally the size of the recycling pool, and not the rate of fusion.
Inhibition of Transmitter Release Requires the
N-Terminal Membrane Binding Domain of Synuclein and
Shows a Linear Dose-Response to Synuclein Expression
The ability of transfected human asyn to inhibit synaptic vesicle
exocytosis provides an experimentally tractable system to iden-
tify the sequences responsible. We first assessed the effect of
three point mutations associated with familial PD (Polymeropou-
los et al., 1997; Kru¨ger et al., 1998; Zarranz et al., 2004), including
the A30P mutation, which has previously been shown to disrupt
the membrane association and synaptic localization of asyn (Jo
et al., 2002; Fortin et al., 2004). Transfected into hippocampal
neurons with VGLUT1-pHluorin, A30P asyn indeed shows no
inhibition of synaptic vesicle exocytosis (Figures 5A and 5B)
despite levels of expression equivalent to the wild-type protein
by immunofluorescence with an antibody to the C terminus
that is not affected by the N-terminal A30P mutation (Fig-
ure S3). Since the A30P mutation disrupts the membrane asso-
ciation of asyn in vivo (Fortin et al., 2004), membrane association
and the associated synaptic enrichment appear required for the
inhibition of transmitter release. The lack of inhibition by A30P
asyn also serves as an additional control for wild-type asyn.
In contrast to A30P asyn, the other PD-associated mutants
A53T and E46K retain membrane binding (Bussell and Eliezer,
2004; Fredenburg et al., 2007) and inhibit transmitter release
(Figure 5B).
The highly charged C terminus of asyn has been suggested to
interact with other proteins such as phospholipase D and the
actin cytoskeleton (Payton et al., 2004) and contains a series ofpotential phosphorylation sites that may influence aggregation
(Chen and Feany, 2005; Smith et al., 2005). However, deletion
of the last 10, 20, and 30 residues has no effect on the inhibition
of transmitter release by asyn (Figures 5C and 5D, data not
shown). The N terminus of asyn thus suffices to inhibit synaptic
vesicle exocytosis, supporting a primary role for the membrane-
binding domain.
Consistent with a role for the more highly conserved N
terminus, we find that overexpression of b-synuclein (bsyn)
also inhibits transmitter release (Figure 5D). Since most neurons
express bsyn as well as asyn, redundancy may thus account for
the minimal effect of the asyn KO on synaptic vesicle exocytosis
described above. To test this possibility, we analyzed a-/b-syn
double KO mice and observe a trend toward increased release
that does not reach significance (Figure 1G).
The similarity of KO and wild-type mice in these and previous
experiments raised the possibility that the effect of asyn on
synaptic transmission may require high levels of expression.
Since the original titration showed expression proportionate to
the amount of cDNA transfected (Figure S1 and data not shown),
we also transfected neurons with one-third the usual amount.
These cells show an inhibition of transmitter release, but to
a lesser extent than neurons expressing more human asyn
(Figures 5E and 5F). In a different set of cultures, we used twice
as much asyn cDNA as usual, and essentially eliminated the fluo-
rescence response (Figure S1D). The inhibition of synaptic
vesicle exocytosis thus exhibits a roughly linear dose-response
to overexpression of synuclein that extends well beyond base-
line levels. In addition to arguing against a threshold effect that
might suggest toxicity, this dose-response predicts that the
knockout should have a small effect on transmitter release that
would be difficult to detect above background variation.
Effects of a-Synuclein on Biochemical Composition
and Ultrastructure of the Nerve Terminal
To determine whether the overexpression of asyn affects the
biochemical composition of the nerve terminal, we took advan-
tage of the transgenic mice. In contrast to the expression of
human asyn by a small proportion of transfected neurons in
culture, the widespread expression in transgenic mice should
make any changes easier to detect. Using quantitative western
analysis, we find no change in the amount of v- and t-SNARE
fusion proteins, the calcium sensor synaptotagmin, SM proteins,
rab3, and other proteins of unknown function such as synapto-
physin and SV2 (Figure 6). The preserved amount of integral
synaptic vesicle membrane proteins further supports the results
of imaging that suggest no effect of asyn on the number of
synaptic vesicles (Figures 1A and 1B) (Rosahl et al., 1995).
However, we do find a specific reduction in the synapsins (espe-
cially synapsin IIb) and complexin 2 (Figure 6). The overexpres-
sion of asyn thus appears to reduce the amount of two peripheral
membrane proteins associated with synaptic vesicles.
We used electron microscopy to assess further the effects of
overexpressed human asyn on synapse ultrastructure, again
relying on the transgenic mice due to the relative uniformity of
overexpression. Relative to the synaptic vesicles of wild-type
mice, which cluster at the active zone, the synaptic vesicles of
transgenic animals show reduced clustering, both in boutonsNeuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc. 71
Figure 5. The N Terminus, but Not the C Terminus,
of a-Synuclein Is Required for the Inhibition of
Synaptic Vesicle Exocytosis
(A) Time course of VGLUT1-pHluorin fluorescence during
a 10 Hz stimulus for 60 s in neurons expressing either
vector, asyn, or the PD-associated mutant A30P.
(B) Peak DF/F0 normalized to the response in vector
control shows that the A30P mutation abolishes the inhibi-
tion of neurotransmitter release by asyn, but the A53T and
E46K mutations have no effect. p < 0.0001 by one-way
ANOVA. p < 0.001 for A30P versus wild-type by Tukey’s
multiple comparison test. n = 180 boutons from 9 cover-
slips per condition and 3 independent transfections.
(C) Neurons transfected with wild-type asyn and the
C-terminal truncation 1-110 also show a similar inhibition
of synaptic vesicle exocytosis relative to vector control.
(D) Peak DF/F0 normalized to the response in vector
control shows that deletion of the C terminus has no effect
on the inhibition of neurotransmitter release by asyn. The
closely related isoform bsyn inhibits neurotransmitter
release to a similar extent. p < 0.01 by one-way ANOVA,
but p > 0.05 for 1-110 and bsyn versus wild-type by
Tukey’s multiple comparison test. n = 120 boutons from
6 coverslips per condition and 2 independent transfec-
tions. Values represent mean ± SEM.
(E) Time course of changes in the fluorescence of
VGLUT1-pHluorin during and after 10 Hz stimulation for
60 s in neurons transfected with 1.5 mg VGLUT1-pHluorin
and either 1.5 mg vector control (vec), 1.5 mg asyn, or
1.0 mg vector and 0.5 mg asyn (0.5 mg asyn). n = 3 cover-
slips, 60 boutons per condition.
(F) PeakDF/F0 values at the end of the stimulus. Values are
normalized to the response in the vector control condition.
n = 3 coverslips, 60 boutons per condition. The bars
indicate mean ± SEM.
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do not (Figures 7B and 7C). The transgenic synapses appear
normal in other respects, with no change in synapse density
(0.75 ± 0.08 in the transgenic versus 0.77 ± 0.08 terminals/
10 mm2 in wild-type, p = 0.79), no aggregates or evidence of
toxicity, although quantitation reveals a slight enlargement of
the postsynaptic density in transgenic mice (Figure 7D). Consis-
tent with the live imaging and the biochemistry, the total
number of synaptic vesicles associated with an active zone
does not differ between wild-type and transgenic (Figure 7E).
However, vesicle density is substantially reduced (Figure 7F).
Quantitation of vesicle density as a function of distance from
the active zone indeed shows that asyn overexpression reduces72 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.the number of vesicles adjacent to the active
zone, but increases those at greater distances
(Figure 7G).
Overexpression of a-Synuclein Affects
the Reclustering of Synaptic Vesicles
after Endocytosis
The effect of asyn overexpression on synaptic
vesicle density and recycling pool size, together
with the lack of specific effect on endocytosis,
suggests that asyn may interfere with a step inthe recycling pathway that follows endocytosis, such as the
reclustering of newly formed synaptic vesicles. To visualize
reclustering directly, we fused GFP to the N terminus of VGLUT1:
in this cytoplasmic location, GFP does not change in fluores-
cence with exo- or endocytosis, enabling it to serve as a reporter
for the position of the protein along the axon. Indeed, previous
work has shown that integral membrane proteins of the synaptic
vesicle disperse with stimulation, consistent with their move-
ment along the plasma membrane following exocytosis (Fortin
et al., 2005). After dispersion, these proteins recluster with
a time course (over 5–15 min) slower than endocytosis (<60 s).
As shown in Figure 8A, GFP-VGLUT1 fluorescence at boutons
declines with stimulation, and the overexpression of asyn
Figure 6. a-Synuclein Causes a Selective Decrease in the Level of
Synapsins and Complexins
Western analysis of brain extracts from asyn transgenic mice and wild-type
littermates using fluorescent secondary antibodies show a reduction in synap-
sins (A) and complexins (B).
(C) Quantitation shows no change in the level of many other synaptic proteins.
n = 3 animals per genotype. Values represent mean ± SEM.
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a-Synuclein Inhibits Neurotransmitter Releasereduces the extent of this decline, consistent with the inhibition
of release. However, normalization to the maximum decline in
fluorescence with stimulation shows that VGLUT1 reclusters
differently with overexpression of asyn (Figure 8B). Although
the average time constant for fluorescence recovery in boutons
that do recover appears no different from controls (trecluster for
asyn 29.7 ± 2.7 s and for control 29.8 ± 2.6 s, p = 0.98), the
number of boutons that show no recovery increases substan-
tially with overexpressed asyn (Figure 8C). aSyn thus affects
the reclustering of synaptic vesicles after endocytosis.
DISCUSSION
The results show that overexpression of asyn inhibits neuro-
transmitter release. Optical imaging of transfected neurons and
electrophysiologic recording from the brain slices of transgenic
mice both indicate a defect in release, consistent with the
presynaptic location of asyn. Using the same experimental para-digm, we find little or no difference between wild-type and asyn
knockout. Relative to the KO, increased expression of asyn
thus appears to have a much greater effect on synaptic vesicle
exocytosis.
Considering the minimal effect of the knockout, why does
synuclein overexpression have a dramatic effect on transmitter
release? First, overexpression could result in toxicity due to the
gain of an abnormal function such as the impaired membrane
trafficking observed in yeast, with indirect effects on transmitter
release (Outeiro and Lindquist, 2003; Willingham et al., 2003;
Cooper et al., 2006; Soper et al., 2008). However, we find no
change in the level of VGLUT1-pHluorin reporter used for optical
imaging of the synaptic vesicle cycle, excluding a major defect in
the early secretory pathway. In addition, we deliberately overex-
pressed asyn in the range predicted for patients with a duplica-
tion or triplication of the gene, reducing the likelihood of toxicity
due to massive accumulation. The similar effects of asyn overex-
pression in transgenic mice also exclude a role for the toxicity of
acute transfection, and support the physiological significance of
these observations for synaptic transmission in vivo. In addition,
we did not detect any inclusions by immunofluorescence or
oligomers by western analysis. The ability of a point mutation
(A30P) to block the inhibition of synaptic vesicle exocytosis by
asyn further supports the specificity of the effect by wild-type.
The lack of change in total synaptic vesicle pool size, endocy-
tosis and the kinetics of exocytosis also argue against nonspe-
cific toxicity.
Second, functional redundancy with bsyn and gsyn may
account for the minimal phenotype of the asyn KO. Indeed, the
three isoforms are very similar in sequence, overlap in distribu-
tion, and double KO mice lacking gsyn as well as asyn show
a substantial increase in dopamine release not observed in single
knockout mice (Senior et al., 2008). Consistent with potential
redundancy, we now find that overexpression of bsyn also
inhibits transmitter release. However, the minimal effect of the
a/bsyn double KO on synaptic vesicle exocytosis and synaptic
transmission (Chandra et al., 2004) makes redundancy unlikely
to account for the lack of detectable effect in the asyn single
KO. Since bsyn has been suggested to protect against the
aggregation of asyn (Hashimoto et al., 2001; Uversky et al.,
2002; Park and Lansbury, 2003), does not produce toxicity,
and is not associated with PD, the ability of bsyn to inhibit trans-
mitter release argues further against a role for toxicity.
Third, the roughly linear inhibition of transmitter release
suggests that the effect of the KO may simply be difficult to
detect. Based on the response to overexpression 2- to 3-fold
above endogenous, the effect of losing synuclein is in fact pre-
dicted to be small, and possibly within the noise associated
with these measurements. Synuclein may thus have an impor-
tant role at baseline. However, the effects of overexpression
also suggest that the endogenous protein may have a particularly
important role when upregulated. Indeed, synuclein upregulates
under a variety of conditions (Vila et al., 2000; Quilty et al., 2006)
including sporadic PD (Chiba-Falek et al., 2006), and our obser-
vations predict dramatic effects on synaptic transmission.
The hydrophilic C terminus of asyn has been suggested to
interact with a number of proteins (Payton et al., 2004; McFar-
land et al., 2008) and to undergo phosphorylation at multipleNeuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc. 73
Figure 7. Overexpression of a-Synuclein Disrupts
Synaptic Vesicle Clustering
(A) An electron micrograph from stratum radiatum of
hippocampal region CA1 in a wild-type mouse shows
clustered vesicles (*) in a terminal (T) closely apposed to
the postsynaptic density of a dendritic spine (S). Although
the nerve terminal and distal axons (A) are relatively large
structures, their synaptic vesicles cluster (*), leaving
most of the axoplasm unoccupied.
(B) In a representative sex-matched transgenic sibling,
synaptic vesicles show less clustering at the active zone
and occupy the full volume of the distal axon (*).
(C) The distal axon of a transgenic mouse shows synaptic
vesicles dispersed into the axon. Scale bar, 100 nm (A–C).
(D) The postsynaptic density (PSD) is slightly longer in
transgenic mice (p < 0.05, n = 217 for wild-type and 199
for transgenic mice). Quantitation of synaptic vesicle
number associated with a particular active zone (E) shows
no significant differences between wild-type and trans-
genic mice (p = 0.37, n = 199, 218).
(F) In contrast, synaptic vesicle density in synaptic bou-
tons of transgenic mice shows a substantial reduction
relative to wild-type (p < 0.0001, n = 217 for wild-type
and 201 for transgenic mice). Bars indicate mean ± SEM.
(G) Histogram with bins indicating the following distances
from the active zone: 1:25–50 nm, 2:50–75 nm, 3:75–
100 nm, 4:100–125 nm, 5:125–150 nm, 6:150–175 nm,
7:175–200 nm, 8:200–225 nm, 9:225–250 nm, 10:250–
275 nm, 11:275–300 nm, 12:300–325 nm, 13:325–350 nm.
n = 2714 vesicles for wild-type and 3193 for transgenic.
A c2 test shows p < 0.05 for bins marked with * and p <
0.0001 for bins marked with ***.
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Chen and Feany, 2005). However, we find that deletion of the
C terminus does not affect the ability of asyn to inhibit synaptic
vesicle exocytosis, excluding a requirement for the C terminus
in this function of asyn, although it might still have a regulatory
role.
Consistent with a crucial role for the N-terminal membrane-
binding domain, the PD-associated A30P mutation abolishes
the inhibition of transmitter release by asyn. Since this mutation
prevents the membrane association of asyn in a number of
experimental systems (Jo et al., 2002; Outeiro and Lindquist,
2003; Kubo et al., 2005) and prevents the synaptic enrichment
of asyn in neurons (Fortin et al., 2004), a high concentration of
the protein at these structures appears essential for the effect
on transmitter release. In adrenal medullary cells, the A30P
mutant still inhibits the exocytosis of chromaffin granules (Larsen
et al., 2006), but this may reflect the compact round shape of74 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.these cells that does not require specific
targeting of synuclein to the release site. The
A30P may thus retain some intrinsic ability to
inhibit release. The inability of PD-associated
A30P asyn to inhibit transmitter release in
neurons raises questions about the relevance
of this activity to the pathogenesis of PD, but
the reduced effect of the A30P mutant may in
fact account for the late onset of disease and
incomplete penetrance observed in familieswith the A30P mutation relative to those with A53T (Kru¨ger
et al., 2001).
How does asyn influence synaptic transmission? Since
hypertonic sucrose elicits release independent of calcium, the
ability of synuclein to inhibit release stimulated by hypertonic
sucrose excludes an effect of synuclein on calcium entry or
the calcium-dependent triggering of release. In addition, asyn
does not alter the kinetics of either synaptic vesicle exo- or
endocytosis. Rather, asyn reduces the size of the synaptic
vesicle recycling pool assessed either with FM4-64 or by
stimulation in the presence of the H+ pump inhibitor bafilomycin.
Since the readily releasable pool shows a proportionate reduc-
tion in size, we infer that this reduction simply reflects the
change in recycling pool. Further, the analysis of VGLUT1-
pHluorin in the presence of NH4Cl, the quantitative analysis of
synaptic vesicle proteins, and the electron microscopy show
that asyn does not reduce the total number of synaptic vesicles.
Figure 8. Overexpression of a-Synuclein Inhibits Synaptic Vesicle
Reclustering after Endocytosis
(A) Time course of the synaptic GFP-VGLUT1 response to 10 Hz, 60 s stimu-
lation in rat hippocampal neurons transfected with either human asyn or vector
control. Inset shows the amplitude of dispersion measured at the end of the
electrical stimulus. ***p < 0.0001 by unpaired, two-tailed t test. n = 131
synapses for vector control and n = 135 synapses from asyn-transfected cells,
9 coverslips each, from 3 independent transfections. Bars indicate mean ±
SEM.
(B) Normalization of the data from (A) to the maximum extent of dispersion
shows that boutons overexpressing asyn exhibit a defect in the extent of
Neuron
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vesicle recycling pool.
Transgenic overexpression of asyn also increases the paired-
pulse ratio. Although changes in PPR are generally considered to
reflect changes in calcium accumulation, the manipulation of
release probability independent of calcium has also been shown
to influence PPR (Rosahl et al., 1993; Augustin et al., 2001). In
addition, the changes in PPR produced by synuclein expression
are much smaller than those produced by manipulating calcium,
presumably because synuclein reduces the entire pool of recy-
cling vesicles as well as the readily releasable pool, limiting the
availability of vesicles for the second pulse.
The analysis of transgenic mice overexpressing asyn shows
a reduced number of synaptic vesicles adjacent to the active
zone, consistent with a defect in vesicle mobilization rather
than fusion. The transgenic mice indeed show a general reduc-
tion in synaptic vesicle clustering, suggesting a physical basis
for the defect in mobilization. How does asyn control synaptic
vesicle clustering and the size of the recycling pool? The bio-
chemical analysis suggests several possibilities.
The transgenic mice overexpressing asyn show a 20%–45%
reduction in the amount of multiple synapsins, and previous
work has implicated the synapsins in synaptic vesicle mobiliza-
tion (Hilfiker et al., 1999). The knockout of synapsin I reduces
recycling pool size by 30%–40% (Ryan et al., 1996). However,
the ultrastructural analyses of synapses from mice lacking either
synapsin I or synapsin II show a reduction in the total number of
synaptic vesicles, distinct from the primary defect in recycling
pool size observed with asyn overexpression (Rosahl et al.,
1995). In addition, the overexpression of asyn appears to cause
a more severe defect in the recycling pool than the complete loss
of synapsins, and the transgenic mice show only a partial reduc-
tion in synapsins. The effect of asyn overexpression is thus
unlikely to reflect simply the loss of synapsins. Rather, asyn
and the synapsins both seem to influence related processes
involved in vesicle mobilization.
Overexpression of asyn also reduces the amount of complexin
2 in the transgenic mice. A change in the level of complexins,
which are implicated in a step at or close to fusion with the
plasma membrane (Sudhof and Rothman, 2009), might thus be
consistent with a proposed role for synuclein as chaperone for
SNARE proteins (Chandra et al., 2005). However, a change in
SNARE protein function seems unlikely to account for the
observed defect in synaptic vesicle mobilization, or the reduced
clustering of synaptic vesicles near the active zone. On the other
hand, a-/b-synuclein double KO mice show a 30% increase in
complexins (particularly complexin 2) (Chandra et al., 2004), sug-
gesting that the reduction in complexin 2 observed in the trans-
genic mice may reflect a gain in the normal function of asyn.reclustering. Inset shows, however, that there is no change in the time constant
tof reclustering. n = 152 synapses for vector control and n = 172 synapses from
asyn-transfected cells, 9 coverslips each from 3 independent transfections.
(C) Distribution of boutons by the extent of reclustering shows that asyn
increases the proportion with reduced reclustering. p < 0.0001 by c2 analysis.
Inset shows the average reclustered fraction. n = 154 synapses for vector
control and n = 168 synapses from asyn-transfected cells, 9 coverslips
each, from 3 independent transfections.
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that synuclein impairs the reclustering of synaptic vesicles after
endocytosis. To visualize this directly, we used a cytoplasmic
fusion of VGLUT1 to GFP rather than the lumenal fusion to
ecliptic pHluorin. Although the steady-state dispersion of
synaptic vesicles observed by electron microscopy might have
resulted from a subtle defect in reclustering that becomes
evident only over time, we observe a clear defect in reclustering
after only a single period of stimulation. The imaging of GFP-
VGLUT1 thus provides information complementary to the
pHluorin fusion, and direct evidence for a defect in synaptic
vesicle reclustering that presumably accounts for the synaptic
vesicle dispersion observed by electron microscopy, and the
reduction in recycling pool size observed by imaging.
Conclusion
These experiments demonstrate that increased expression of
asyn causes a specific physiological impairment of neurotrans-
mitter release in the absence of overt toxicity. It remains unclear
whether this functional disturbance leads eventually to anatom-
ical degeneration. However, considerable evidence implicates
increased expression of asyn in the pathogenesis of sporadic
as well as familial PD, indicating that the changes observed
must represent some of the earliest events in the progression
toward PD. The results also suggest an explanation for the ability
of asyn to protect against degeneration caused by loss of the
presynaptic chaperone cysteine string protein alpha (CSPa)
(Chandra et al., 2005). CSPa appears required for the mainte-
nance of presynaptic function but not for transmitter release
itself: synaptic transmission in the CSPa KO appears normal
early in development, but the terminals eventually degenerate
(Ferna´ndez-Chaco´n et al., 2004). CSPa thus has an activity-
dependent role in maintenance of the nerve terminal, and the
inhibition of release caused by asyn overexpression may simply
decrease the requirement for CSPa. Importantly, overexpression
of A30P asyn was unable to rescue the loss of CSPa (Chandra
et al., 2005), presumably because the A30P mutant cannot
inhibit transmitter release.
Since asyn is widely expressed, the results predict that indi-
viduals carrying a duplication or triplication of the gene will
show changes from an early age in the function of many neural
circuits. In sporadic PD, where upregulation of asyn may first
occur in only a subset of cells that normally express the protein
(Braak et al., 2003), the deficit may be more restricted. Nonethe-
less, physiological defects may prove more sensitive than
anatomic or even biochemical changes as early markers for
PD, and serve as targets for early, therapeutic intervention.
EXPERIMENTAL PROCEDURES
Neuronal Culture and Transfection
Primary hippocampal cultures were prepared as previously described (Li et al.,
2005). For cotransfection, 1.5 mg VGLUT1-pHluorin DNA and 1.5 mg pCAGGS
or pCAGGS-asyn DNA were used per 33 106 cells. For experiments using FM
dyes, neurons were grown as above but plated at 177–283 cells/mm2 and
grown inverted over a monolayer of glial cells (Banker and Goslin, 1998).
To prepare hippocampal cultures from mice, hippocampi from P0–P1 asyn
KO mice or wild-type littermates were dissociated in 0.25% trypsin, washed
several times in HBSS containing 10 mM HEPES and 20 mM glucose,76 Neuron 65, 66–79, January 14, 2010 ª2010 Elsevier Inc.triturated, and electroporated with 0.6 mg total DNA per 500,000 cells (Amaxa).
In cotransfection experiments, 0.3 mg VGLUT1-pHluorin DNA and 0.3 mg
pCAGGS or pCAGGS-asyn DNA were used. After transfection, cells were
allowed to recover for 10 min and plated in MEM containing 21 mM glucose,
5% FBS, 2% B27, 1% Glutamax, and Mito+ serum extender (BD Biosciences)
at a density of 1768 cells/mm2 onto coverslips coated with poly-L-lysine
(Sigma). Cultures were maintained with 5-FU and uridine containing media
as described above for rat-derived cultures.
Postnatal rat midbrain cultures were prepared from the ventral mesenceph-
alon of P0–P1 rats as described (Mena et al., 1997) and electroporated with
0.6 mg total DNA per 500,000 cells (Amaxa) before plating onto astrocyte
feeder layers at a density of 1415–2830 cells/mm2.
Live Cell Imaging
Transfected neurons were imaged between 14–21 DIV at room temperature
(24C) as previously described (Voglmaier et al., 2006) unless otherwise
stated. For imaging at a more physiological temperature, the stage was
warmed to 35C using the TC-344B Dual Automatic Stage Temperature
Controller (Warner Instrument). Images were obtained under epifluorescence
illumination with a 633 1.2NA water objective and an ORCA ER CCD camera
(Hamamatsu), using 23 2 on-chip pixel binning. The fluorescence of individual
synaptic boutons was quantified by placing 4 3 4 ROIs manually over the
center of fluorescent puncta. The fluorescence in these regions was averaged,
subtracted by the average of three ROIs over regions of the field without cell
bodies or processes, and the fractional change in fluorescence over time
normalized to the initial fluorescence (DF/F0). Traces represent a single exper-
iment in which 20 boutons were selected per coverslip, and the data from three
coverslips averaged. To quantify peak DF/F0, 20 boutons were selected per
coverslip, and nine coverslips from three independent transfections were
averaged. All imaging and quantitation was performed blind to the construct
transfected.
To measure recycling pool size using FM4-64, neurons transfected with
either pCAGGS-IRES2-GFP or pCAGGS-asyn-IRES2-GFP were incubated
in Tyrode’s buffer containing 15 mM FM4-64 and stimulated at 10 Hz for
60 s. The dye was washed out 1 min after the end of stimulation to allow full
internalization and the cells washed in Tyrode’s buffer for an additional
10–15 min before unloading at 10 Hz for 120 s. The pool size was determined
by quantifying the amount of FM fluorescence released by the second stimulus
at boutons expressing GFP.
To quantify recycling and total pool size using VGLUT1-pHluorin,
neurons transfected with either VGLUT1-pHluorin + vector control or
VGLUT1-pHluorin + asyn were stimulated at 10 Hz for 150 s in the presence
of 1 mM bafilomycin (Calbiochem) to reveal total recycling pool size. At the
end of the stimulus, Tyrode’s containing 50 mM NH4Cl was added to reveal
the total size of the synaptic vesicle pool.
To assess synaptic vesicle dispersion, neurons transfected with VGLUT1-
GFP and either vector control or asyn were stimulated at 10 Hz for 60 s in
Tyrode’s solution containing 25 mM HEPES and 119 mM NaCl. Images were
collected as above for 10 min at 0.2 Hz under epifluorescence illumination
with a 1003 1.49 NA oil objective. The fluorescence at nerve terminals was
quantified by outlining the perimeter of synaptic boutons and calculating the
average fluorescence intensity. The extent of dispersion (D) was determined
by averaging five DF/F0 values surrounding the peak of fluorescence change.
The extent of reclustering (R) was determined by measuring the fluorescence
plateau after stimulus cessation. The reclustering fraction (Fr) was calculated
as Fr = RD/D. The kinetics of reclustering were analyzed only for those bou-
tons where the fluorescence recovery was fit by a single exponential A – B
(1 – e–kt). Boutons that did not display fluorescence recovery or whose
recovery did not fit a single exponential were grouped in bin 100 (Figure 8C).
Electrophysiology
Transverse 300–400mm hippocampal slices were prepared from 24- to 36-day-
old animals hemizygous for the humanasyn transgene and from wild-type litter-
mates, and field EPSPs evoked in CA1 stratum as previously described (Lu
et al., 2009). Slices from transgenic mice and wild-type littermates were inter-
leaved, and the experimenter was blind to genotype. mEPSCs were monitored
by whole cell recording, also as previously described (Lu et al., 2009).
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